Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DnaJ heat shock protein family member C21 (DNAJC21) is a ubiquitously expressed nuclear and cytoplasmic co-chaperone involved mainly in rRNA biogenesis and the maturation of the 60S ribosomal subunit. DNAJC21 binds precursor 45S rRNA, associates with key cofactors such as PA2G4, ZNF622, and HSPA8, and is essential for proper nucleo-cytoplasmic transport and final maturation of ribosomal subunits. Germline mutations cause a cancer-prone bone marrow failure syndrome, manifesting as hematopoietic defects, cytopenia, impaired cell growth, and increased disease risk, particularly acute myeloid leukemia. Deficits in DNAJC21 lead to abnormal ribosome profiles, cell death, and increased sensitivity to ribosome synthesis inhibitors, highlighting its fundamental role in cellular protein homeostasis and human disease[1][2][3].
Drugs that affect ribosomal RNA synthesis (such as Actinomycin D) can have increased cytotoxicity in DNAJC21-deficient cells due to impaired rRNA biogenesis[1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DnaJ heat shock protein family member C21 (DNAJC21).